Vanguard Capital Management’s Aprea Therapeutics APRE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$36.9K Buy
49,212
+26,330
+115% +$19.1K ﹤0.01% 3936
2026
Q2
$18.4K Buy
22,882
+3,260
+17% +$2.72K ﹤0.01% 4016
2026
Q1
$15K Buy
+19,622
New +$15.4K ﹤0.01% 3999

Other funds holding APRE

Vanguard Capital Management's APRE Position: Q3 2026 in Review

Vanguard Capital Management increased its Aprea Therapeutics (APRE) stake by 115% in Q3 2026, buying an estimated $19.1K and bringing the position to 49,212 shares worth $36.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3936.

Vanguard Capital Management first reported a position in APRE in Q1 2026 and has held it in 3 quarters since. 27 funds tracked by Wall St. Rank hold APRE as of Q3 2026.

  • Vanguard Capital Management held 49,212 shares of Aprea Therapeutics worth $36.9K as of Q3 2026.
  • Vanguard Capital Management bought 26,330 Aprea Therapeutics shares in Q3 2026, an estimated $19.1K.
  • Aprea Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3936 holding.
  • Vanguard Capital Management first reported a position in Aprea Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 27 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.